Page last updated: 2024-11-08

cp 320626

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CP 320626: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID444746
CHEMBL ID99889
SCHEMBL ID7234251
MeSH IDM0368695

Synonyms (21)

Synonym
CHEMBL99889 ,
(s)-5-chloro-n-(3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl)-1h-indole-2-carboxamide
5-chloro-1h-indole-2-carboxylic acid [(s)-1-(4-fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-amide
bdbm35346
5-chloro-1h-indole-2-carboxylic acid [1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1yl)-2-oxoethyl]amide
DB03383
cp-320626
5-chloro-n-[(2s)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1h-indole-2-carboxamide
5-chloro-n-((2s)-3-(4-fluorophenyl)-1-(4-hydroxy-1-piperidinyl)-1-oxo-2-propanyl)-1h-indole-2-carboxamide
1h-indole-2-carboxamide, 5-chloro-n-((1s)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-
cp 320626
186430-23-9
fkx709rk3q ,
unii-fkx709rk3q
1h-indole-2-carboxamide, 5-chloro-n-(1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-, (s)-
SCHEMBL7234251
5-chloro-n-[(1s)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1h-indole-2-carboxamide
YDCGVASFVACWKF-NRFANRHFSA-N ,
5-chloro-1h-indole-2-carboxylic acid [(1s)-(4-fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-amide
Q27094321
AKOS040751273

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Compound 25e(alpha) also had an excellent pharmacokinetic profile, with high oral bioavailability and a long plasma half-life, in male SD rats."( Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
Furutani, M; Hamada, N; Katayama, N; Momose, K; Ogiyama, T; Ohta, M; Okada, M; Onda, K; Orita, M; Shiraki, R; Takeuchi, M; Tsukamoto, S; Yamaguchi, T; Yokoyama, K, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycogen phosphorylase, liver formHomo sapiens (human)IC50 (µMol)1.24070.08201.16594.8000AID101846; AID101849; AID1799312; AID1799323; AID388287; AID408585
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)4.00000.05001.43904.0000AID322753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID113922Percent decrease in drug -treated plasma glucose concentration, relative to vehicle treated control diabetic ob/ob mice1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
AID408585Inhibition of human liver glycogen phosphorylase a2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
AID388288Inhibition of glucagon-induced glucose output in cultured rat primary hepatocytes2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
AID109739Hypoglycemic responses resulting from oral dosing in diabetic ob/ob mice(active dose), po1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
AID141124Inhibition of Rabbit muscle glycogen phosphorylase B.2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
AID388291Hypoglycemic activity in db/db mouse assessed as reduction of plasma glucose at 30 mg/kg, po after 2 hrs relative to control2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
AID408586Inhibition of glucagon-induced glycogenolysis in Sprague-Dawley rat hepatocytes2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
AID101846In vitro inhibitory activity against recombinant human liver glycogen phosphorylase a (rHLGPa) catalyzed release of phosphate from glucose-1-phosphate.1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID408587Hypoglycemic activity against C57BL/KsJ db/db mouse assessed as reduction of blood glucose at 50 mg/kg, po after 2 hrs relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
AID109740Hypoglycemic responses resulting from oral dosing in diabetic ob/ob mice(inactive dose), po1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
AID101849In vitro inhibition of pig liver Glycogen phosphorylase A.2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
AID201648Inhibition of forskolin-stimulated glycogenolysis in SK-HEP-1 cells1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
AID388287Inhibition of active form of human liver glycogen phosphorylase2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
AID1799312Glycogen Phosphorylase Activity Assay from Article 10.1016/j.bmc.2008.10.021: \\Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.\\2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
AID1799323Glycogen Phosphorylase Activity Assay from Article 10.1016/j.bmc.2008.04.010: \\Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.\\2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's15 (83.33)29.6817
2010's2 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]